Mene Pangalos, AstraZeneca EVP, BioPharmaceuticals R&D
AstraZeneca picks up Pfizer’s rare disease gene therapies, taps new R&D leader as Mene Pangalos steps down
AstraZeneca’s Alexion subsidiary is snapping up a suite of Pfizer’s preclinical gene therapies in a move to expand its toolkit in rare disease R&D. …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
